The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Susan F. Slovin

Genitourinary Oncology Service

Department of Medicine

Sidney Kimmel Center for Prostate and Urologic Cancers

Memorial Sloan-Kettering Cancer Center



Name/email consistency: high



  • Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, USA. 2009
  • Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, USA. 1999 - 2009
  • Genitourinary Solid Tumor Service, 1275 York Ave, New York, NY 10021, USA. 2003


  1. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Slovin, S.F., Kelly, W.K., Wilton, A., Kattan, M., Myskowski, P., Mendelsohn, J., Scher, H.I. Clin. Genitourin. Cancer (2009) [Pubmed]
  2. Pitfalls or promise in prostate cancer immunotherapy-which is winning?. Slovin, S.F. Cancer. J (2008) [Pubmed]
  3. Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?. Slovin, S.F. Expert. Rev. Anticancer. Ther (2008) [Pubmed]
  4. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Slovin, S.F., Ragupathi, G., Fernandez, C., Diani, M., Jefferson, M.P., Wilton, A., Kelly, W.K., Morris, M., Solit, D., Clausen, H., Livingston, P., Scher, H.I. Cancer Immunol. Immunother. (2007) [Pubmed]
  5. Emerging role of immunotherapy in the management of prostate cancer. Slovin, S.F. Oncology (Williston Park, N.Y.) (2007) [Pubmed]
  6. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. Slovin, S.F. Nat. Clin. Pract. Oncol (2007) [Pubmed]
  7. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome. Slovin, S.F. Clin. Adv. Hematol. Oncol (2007) [Pubmed]
  8. Violaceous exanthem as a manifestation of metastatic prostate cancer in skin. Slovin, S.F., Galsky, M.D., Busam, K. Urology (2006) [Pubmed]
  9. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?. Slovin, S.F. Nature Clinical Practice. Urology (2006) [Pubmed]
  10. Immunologic targeting: how to channel a minimal response for maximal outcome. Slovin, S.F. Curr. Opin. Urol (2006) [Pubmed]
  11. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Slovin, S.F., Ragupathi, G., Musselli, C., Fernandez, C., Diani, M., Verbel, D., Danishefsky, S., Livingston, P., Scher, H.I. Cancer Immunol. Immunother. (2005) [Pubmed]
  12. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Slovin, S.F., Ragupathi, G., Fernandez, C., Jefferson, M.P., Diani, M., Wilton, A.S., Powell, S., Spassova, M., Reis, C., Clausen, H., Danishefsky, S., Livingston, P., Scher, H.I. Vaccine (2005) [Pubmed]
  13. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Slovin, S.F. Expert Opin. Ther. Targets (2005) [Pubmed]
  14. Carbohydrate vaccines as immunotherapy for cancer. Slovin, S.F., Keding, S.J., Ragupathi, G. Immunol. Cell Biol. (2005) [Pubmed]
  15. Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico. Slovin, S.F. IDrugs (2005) [Pubmed]
  16. Prostate-specific membrane antigen vaccines: naked DNA and protein approaches. Slovin, S.F. Clin. Prostate. Cancer (2005) [Pubmed]
  17. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Slovin, S.F., Wilton, A.S., Heller, G., Scher, H.I. Clin. Cancer Res. (2005) [Pubmed]
  18. Cancer immunotherapeutics meeting. Slovin, S.F. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  19. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. Slovin, S.F., Ragupathi, G., Musselli, C., Olkiewicz, K., Verbel, D., Kuduk, S.D., Schwarz, J.B., Sames, D., Danishefsky, S., Livingston, P.O., Scher, H.I. J. Clin. Oncol. (2003) [Pubmed]
  20. Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Slovin, S.F. Hematol. Oncol. Clin. North Am. (2001) [Pubmed]
  21. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Slovin, S.F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W.G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K.O., Livingston, P.O., Danishefsky, S.J., Scher, H.I. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
WikiGenes - Universities